Lucy Roalfe, United Kingdom

University College London Research

Poster Author Of 1 e-Poster

 ePoster
Online Abstracts Vaccines - Pneumococcal Vaccines Development C1 Pneumococcal Vaccines Development

SEQUENTIAL ADMINISTRATION OF PREVNAR 13™ AND PNEUMOVAX™ 23 IN HEALTHY PARTICIPANTS 50 YEARS OF AGE AND OLDER

Presenter
Authors
Presentation Type
Abstract_Submission
Presentation Topic
C1 Pneumococcal Vaccines Development

Author Of 4 Presentations

 Conference Calendar

HEAD-TO-HEAD COMAPRISON OF TEN-VALENT (PCV10) AND 13-VALENT (PCV13) PNEUMOCOCCAL CONJUGATE VACCINE FOLLWING TWO-DOSE PRIMARY SERIES AND AFTER BOOSTER- DOSE IN SOUTH AFRICA: RANDOMISED CONTROLED TRIAL (ID 1164)

Session Name
Vaccines - Pneumococcal Vaccines Development
Presenter
Authors

SEQUENTIAL ADMINISTRATION OF PREVNAR 13™ AND PNEUMOVAX™ 23 IN HEALTHY PARTICIPANTS 50 YEARS OF AGE AND OLDER (ID 490)

Session Name
Vaccines - Pneumococcal Vaccines Development
Presenter
Authors

Abstract

Background

Widespread use of the 13-valent pneumococcal conjugate vaccine (PCV13) in infants and the associated indirect protection in adults has highlighted the significant burden of pneumococcal disease caused by serotypes unique to 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults.

Methods

This study evaluated the safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 either 8 weeks (Group#1) or 26 weeks (Group#2) later in adults ≥50 years old. Serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) were measured prior and 30 days postvaccination.

Results

Proportions of participants reporting any AE were comparable between both groups. More participants in Group#1 (81.9%) reported injection site AEs following PPSV23 than Group#2 (64.0%). At Week 12, OPA GMTs to 12 shared serotypes between PPSV23 and PCV13 in Group#1 were noninferior to Group#2; OPA GMTs to 6 serotypes unique to PPSV23 were superior in Group#1 than Group#2. Overall, OPA GMTs for all tested serotypes were comparable by Week 30, after both groups had received PCV13 and PPSV23.

Conclusions

Sequential administration of PCV13 followed by PPSV23 at 2-month or 6-month intervals was generally well-tolerated. Serotype-specific OPA GMTs were comparable, regardless of dosing interval. Administration of PPSV23 did not hinder immune responses induced by PCV13.

Hide

PNEUMOCOCCAL CARRIAGE AND ANTIBODY PERSISTENCE FOLLOWING PCV13 DELIVERED AS ONE PRIMARY AND ONE BOOSTER (1+1) VERSUS TWO PRIMARY DOSES AND A BOOSTER IN UK INFANTS (ID 900)

Session Name
Vaccines - Pneumococcal Vaccines Development
Presenter
Authors

IMMUNOGENICITY OF SINGLE COMPARED TO TWO-DOSE PRIMARY SERIES FOLLOWED BY BOOSTER DOSE OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV) IN SOUTH AFRICA: OPEN-LABEL, RANDOMISED, NON-INFERIORITY TRIAL (ID 1153)

Session Name
Vaccines - Pneumococcal Vaccines Development
Presenter
Authors